Drug decision

• Health & Medicine

First immunotherapy approved for cervical cancer in England and Scotland

The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland. The immunotherapy pembrolizumab may help some people with incurable cervical cancer live longer. It's now an approved treatment for them in England and Scotland.

16 May 2023

• Health & Medicine

Olaparib approved for 800 prostate and breast cancer patients in England

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England.  Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

11 April 2023

• Health & Medicine

NICE recommends pembrolizumab for 1,600 more people with breast cancer

The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales. The "potentially life-saving" immunotherapy drug pembrolizumab is now recommended for some people with early triple negative breast cancer in England and Wales.

14 November 2022

• Health & Medicine

New treatment for Waldenstrom’s macroglobulinaemia in England

1 October 2022

• Health & Medicine

NICE doesn’t recommend olaparib for patients with certain prostate cancers

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

13 September 2022

• Health & Medicine

New targeted treatment for early breast cancer could reduce risk of relapse

A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning. A targeted cancer drug has been approved to treat some people with breast cancer that has a high-risk of returning.

21 July 2022

• Health & Medicine

NICE doesn’t recommend ibrutinib drug for those with Waldenstrom’s macroglobulinaemia

Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England Ibrutinib, a drug used to treat Waldenstrom’s macroglobulinaemia, is not being recommended by the National Institute for Health and Care Excellence in England

23 May 2022

• Health & Medicine

Triple negative breast cancer drug given initial ‘no’ for NHS in England

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer. Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

8 April 2022

• Health & Medicine

Immunotherapy treatment fast tracked to treat lung cancer patients in England

Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England. Hope for patients with early-stage lung cancer as new treatment approved for use on NHS England.

28 January 2022

• Health & Medicine

First targeted treatment approved for advanced prostate cancer on NHS in Scotland

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland. The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

13 October 2021